<DOC>
	<DOCNO>NCT01075048</DOCNO>
	<brief_summary>ARQ 197 placebo combination irinotecan cetuximab patient metastatic colorectal cancer ( CRC ) , subject wild-type KRAS allele fail front-line systemic therapy , evaluate safety , tolerability , efficacy ARQ 197 , define recommend dose Phase 2 .</brief_summary>
	<brief_title>ARQ 197 Combination With Chemotherapy Patients With Metastatic Colorectal Cancer</brief_title>
	<detailed_description>Phase 1/2 Multicenter study : - Phase 1 portion open-label evaluate safety ARQ 197 administer combination irinotecan cetuximab . - Phase 2 portion design randomize , double-blind placebo-controlled study ass efficacy safety ARQ 197 match placebo administer combination irinotecan cetuximab .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>1 . Subjects surgically unresectable locally advanced metastatic disease receive one prior line chemotherapy . ( The Phase 1 portion study open enrollment subject receive 1 prior therapy ) . Both relapsed refractory CRC allow . 2 . All subject must express wildtype form gene KRAS . 3 . Measurable disease accord RECIST ( Response Evaluation Criteria In Solid Tumors ) criterion , Version 1.1 . 4 . Male female &gt; = 18 year age . 5 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . 6 . Resolution toxic effect prior therapy ( except alopecia ) NCI CTCAE , Version 4.0 , grade &lt; = 1 . 7 . Adequate bone marrow , liver , renal function , define : Hemoglobin &gt; = 9.0 g/dL ( transfusion and/or growth factor support allow ) . Absolute neutrophil count ( ANC ) &gt; = 1.5 x 10^9/L . Platelet count &gt; = 75 x 10^9/L . Serum creatinine &lt; = 1.5 x upper limit normal ( ULN ) creatinine clearance &gt; = 60 mL/min . Alanine transaminase ( ALT ) , aspartate transaminase ( AST ) , alkaline phosphatase &lt; = 2.5 x ULN subject liver metastasis &lt; = 5.0 x ULN subject liver metastasis . Total bilirubin &lt; = 1.5 x ULN ( &lt; = 4 x ULN direct bilirubin &lt; = 1.5 x ULN acceptable subject Gilbert 's syndrome ) . 8 . Male female subject childbearing potential must agree use doublebarrier contraceptive measure , oral contraception , avoidance intercourse study 90 day last investigational drug dose receive . 9 . All female subject childbearing potential must negative pregnancy test ( serum urine ) result initiate study treatment . 10 . Subjects must fully inform illness investigational nature study protocol ( include foreseeable risk possible side effect ) must sign date Independent Ethics Committee ( IEC ) Institutional Review Board ( IRB ) approve informed consent form ( ICF ) ( include HIPAA authorization , applicable ) performance study specific procedure test . 1 . Prior therapy Epidermal Growth Factor Receptor ( EGFR ) inhibitor . 2 . History malignancy CRC , unless exception malignancy cure tumorspecific treatment malignancy administer within 5 year prior initiation study treatment ( subject history basal cell carcinoma benign tumor cervix enrol diagnosis treatment occur less 3 year prior randomization ) . 3 . Anticipation need major surgical procedure radiation therapy ( RT ) study . 4 . Treatment chemotherapy , radiotherapy , surgery , immunotherapy , biological therapy , investigational anticancer agent within 4 week prior start study treatment . 5 . History cardiac disease : Congestive heart failure define Class II IV per New York Heart Association ( NYHA ) classification . Active coronary artery disease ( CAD ) . Previously diagnose bradycardia cardiac arrhythmia define Grade 2 high accord NCI CTCAE , version 4.0 , uncontrolled hypertension . Myocardial infarction occur within 6 month prior start study treatment ( myocardial infarction occur great 6 month start study treatment permit ) . 6 . Malabsorption syndrome , chronic diarrhea ( last great 4 week ) , inflammatory bowel disease , partial bowel obstruction . 7 . Known metastatic brain meningeal tumor , unless subject great 6 month definitive therapy , negative imaging study within 4 week first dose study treatment , clinically stable ( concomitant therapy , include supportive therapy steroid anticonvulsant medication ) respect tumor time first dose study treatment . 8 . Uncontrolled seizure disorder , spinal cord compression , carcinomatous meningitis . 9 . Pericardial pleural effusion ( eg , require drainage ) pericardial involvement tumor . Subjects minimal pleural effusion may eligible upon request Investigator approval Sponsor . 10 . Clinically significant active infection require antibiotic therapy . 11 . Previous administration ARQ 197 . 12 . Substance abuse medical , psychological social condition may , opinion Investigator , interfere subject 's participation clinical trial evaluation clinical trial result . 13 . Any condition unstable could jeopardize safety subject subject 's protocol compliance include know human immunodeficiency virus ( HIV ) , hepatitis B virus ( HBV ) , hepatitis C virus ( HCV ) infection . 14 . Inability swallow oral medication . 15 . Pregnant nursing female .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Colorectal cancer</keyword>
	<keyword>wild-type KRAS</keyword>
	<keyword>irinotecan</keyword>
	<keyword>cetuximab</keyword>
	<keyword>second-line therapy</keyword>
</DOC>